Schlagwort: medical

Close to the Customer – ODU to expand market in Korea

As of January 1, 2019 ODU has established its newest ODU company in Korea. Kai Schneider is Managing Director of ODU Korea Inc. Together with the longstanding trading partners it is his task to further expand sales in Korea, to find new sales channels and to introduce ODU connector solutions into Korean medical technology and robotics. "Currently, we are strong in Korea, especially in the field of e-mobility and military technology. We also want to prove our know-how in new fields and applications", says Kai Schneider.

Schneider is a mechanical engineer and brings a lot of experience in mechanical engineering as well as his knowledge of Korean culture. With its new company, ODU wants to be ready and personally accessible to its customers and partners. Kai Schneider will act as the interface between Korea and ODU in Mühldorf (Bavaria). "We also care about the geographical closeness to the customer. We already are present in Japan and China, and that has proven to be successful", says Denis Giba, ODU Managing Director. As a specialist for electrical connector systems, ODU develops solutions exactly to customers’ requirements and specifications. In close cooperation ODU creates technically and economically optimal connector systems that meet the customer needs.

 

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Smart Galvanometer Scanner for Medical and Scientific Applications

SCANLAB GmbH, market-leading OEM manufacturer of advanced laser scan systems, presents its latest offering in the galvanometer product range: the compact dynAXIS 421. The small sized galvo is especially suited to applications in the medical environment – from Optical Coherence Tomography (OCT) to microscopy, DNA-sequencing and other medical laser treatments. The superior motor design with analog or digital servo-control technology, together with ISO 9001-certified quality standards, guarantees highest reliability and extraordinary precision. Digital system monitoring and customizable feedback signals offer an appropriate solution for demanding bio-medical and industrial customers.

Medical applications have special requirements to ensure patient comfort and safety. Therefore precision and long-term reliability are particularly important. Improved scan efficiency, resulting in shorter treatment times and higher quality imaging are especially beneficial in the biomedical sector.

The new compact galvanometer scanner dynAXIS 421 meets the market needs at a reasonable cost target. When combined with SCANLAB’s digital servo-controller, the galvo provides highest dynamics. The new optical position detector results in superior precision and stability. System status monitoring is a flexible feature which can be tailored to the application needs. Low heat generation and optimized thermal resistance ease the integration into handheld devices or complex medical and ophthalmic instruments.

Thanks to SCANLAB’s lean organization, lead times are not only shorter than market average, but are highly dependable. ‘Made in Germany’ proves highest quality standards and consistency across the entire product range. Experienced sales engineers and an application support team provide quick and detailed responses, and customization as needed.

The compact dynAXIS 421 may be purchased with either analog or digital servo-driver boards and a large variety of mirrors and coating options. Standard configurations are available now.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Richard Wolf at ARAB HEALTH 2019

At ARAB HEALTH in Dubai from 28 to 31 January 2019, Richard Wolf GmbH will be presenting its innovative system solutions for minimally invasive human medicine, which visitors can experience both live and virtually.   In addition to the classic product presentation, the medical technology company is increasingly focusing on the digital experience of its topics at trade fairs and congresses and will continue to expand this area in the future. Interested visitors can, for example, experience Richard Wolf’s high-resolution ENDOCAM Logic 4K camera system either in a virtual tour using VR glasses or inform themselves in the usual product exhibition.   The area of extracorporeal shockwave lithotripsy (ESWL) can also be experienced via virtual reality (VR). During the VR tour, the visitor is in a treatment room equipped with a complete PiezoLith 3000plus system. During the simulation, the visitor has the possibility to virtually perform an ESWL on a patient with kidney stones. The treatment can be carried out either with ultrasound or X-ray imaging.   The presentation of product solutions such as the network-based OR integration system core nova, the powerful Holmium:YAG laser MegaPulse 70+ and the innovative solutions for minimally invasive spinal surgery round out Richard Wolf’s overall presence at the largest and most important healthcare congress in the Middle East.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Medical Cannabis Products: How Much Really Gets There?

More and more companies and entrepreneurs operating in the field of Cannabis realize that while the market for ‘flowers’ and ‘extracts’ is significant (and likely to grow), the true ‘holy grail’ lies in the area of cannabis-based therapies.

Among the many questions faced by any company developing a new drug, probably the most complicated are those related to the behavior of their drug in the human body. This is the field of ADME: Absorption, Distribution, Metabolism and Excretion, or, in other words, “How much really gets there?” and where is actually “There”?

One of the tools for obtaining information related to the ADME behavior of the drug, is to determine the levels of compounds of interest in various biological tissues and fluids – i.e., Bioanalytics. In pre-clinical (animal) studies, this can include the analyses of plasma, urine, feces, skin, internal organs and brain. Clinical (human) studies usually include plasma, urine and feces. One of the greatest challenges of determining the levels of cannabinoids in the body, is the highly sensitive detection levels required.   

Analyst Research Laboratories, with its more than 2 decades of experience in the Pharmaceutical, Bioanalytical and Analytical arena, is employing this vast experience to the area of Medical Cannabis.

With in-house validated Bioanalytical and Analytical methods for a variety of cannabinoids, species and tissues, Analyst is routinely supporting its customers from Israel and abroad in their Pre-Clinical and Clinical studies.

If you are developing a new formulation or product, planning a pre-clinical or clinical trial, we will be more than happy to discuss your needs and see if we can help you.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

New ODU Production Site In Sibiu

The new production hall was completed right on time at the end of September last year and successfully approved by local authorities. The move into the brand-new ODU Romania facility in Sibiu was successful and a smart one. The new building offers far more production space (+ 30% in phase 1), with short paths and a clear structure, providing a great deal of flexibility and room for further expansion.

„One of the challenges was to design our very first green field production site outside of Germany,” explains Adrian Costin, Managing Director of ODU Romania in Sibiu. “It worked out 100 % and the production site is working 100 % within the international production network of the ODU Group.” The ODU Group is one of the leading international suppliers of connection systems, data and signal transmission systems. For more than 75 years, ODU has been developing electrical connectors, an essential part of our day-to-day life. Without connectors, no smartphone, appliance or medical equipment would be able to function. Without connectors, cars could not start and industry would not work automatically. Connectors are in numerous applications and areas and it takes just one close look to see that above all, connector technology must be reliable.

The original ODU location in Sibiu was set-up in 2006 operating under the name ODU Romania Manufacturing S.R.L. The new site is situated very close to the international airport of Sibiu, easily accessible and close to the city center. More than 550 people work for ODU in Sibiu.

The company is continuously evolving into a competence center for connectors and cable assembly. Thanks to innovation, continuous improvement and high quality production processes, the manufacturing unit is expanding.

The new and modern production unit in the new industrial park in Sibiu covers the size of 48.000 qm². The production equipment is according to the latest ODU standards securing the high quality standard. It includes social spaces, a cafeteria and 120 parking spaces. „For ODU a good workplace represents an environment where people can grow and the word “team” has a deeper meaning. The values promoted are an open organizational culture and personal development“, says Costin.

ODU is an employer that recognizes and awards professional performance in a company that provides safety and supports individual needs accordingly to governing principles: reliability, equity, responsibility and quality are reference points for cooperation within the company.

The ODU Group headquarter is located in Mühldorf am Inn (Bavaria). From there, the company sells its products all over the world, since „Made in Germany” is an important feature on foreign markets.

Besides the Mühldorf location, ODU has three other international production units in, San Diego (USA), Shanghai (China) and Tijuana (Mexico).

The distribution network includes ten sales companies in Germany, France, Italy, Denmark, Sweden, Great Britain, China, Japan, Korea and the USA. ODU has over 2.300 employees globally and generates annual revenues of 200 million euros.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

Ravenquest’s George Robinson appointed acting President & CEO of Bonify

RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) announces George Robinson, CEO, has been named interim President & CEO of Bonify Medical Cannabis (BMC), Ltd. (“Bonify”).

Bonify Chairman, Jeffery Dyck, stated that “George Robinson’s knowledge and experience is superb when it comes to cannabis production pursuant to Health Canada regulations.  In the wake of our recent product recall, Robinson and his team at RavenQuest have been instrumental in preserving Bonify’s licenses to cultivate, process and sell cannabis.”

“The appointment of Mr. Robinson as acting President & CEO of Bonify is a natural evolution as our organization takes corrective action to emerge as a stronger, compliant and operationally sound licensee moving forward” Dyck continued.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.  RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.  RavenQuest maintains a research partnership with Montreal’s McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including statements with respect to any future performance of Bonify.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com.  Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

George Robinson von RavenQuest zum President und CEO von Bonify ernannt

RavenQuest BioMed Inc. (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT – http://www.commodity-tv.net/c/search_adv/?v=298617) („RavenQuest“ oder das „Unternehmen“) gibt bekannt, dass CEO George Robinson zum interimistischen President und CEO von Bonify Medical Cannabis (BMC) Ltd. („Bonify“) ernannt wurde.

Jeffery Dyck, Chairman von Bonify, sagte: „Das Know-how und die Erfahrung von George Robinson sind einzigartig, wenn es um die Cannabisproduktion gemäß den Health Canada-Bestimmungen geht.  Im Rahmen unseres jüngsten Produktrückrufs haben Robinson und sein Team von RavenQuest maßgeblich dazu beigetragen, die Lizenzen von Bonify für den Anbau, die Verarbeitung und den Verkauf von Cannabis aufrechtzuerhalten.“

„Die Ernennung von Herrn Robinson zum President und CEO von Bonify ist eine natürliche Entwicklung, zumal unser Unternehmen Korrekturmaßnahmen ergreift, um sich als stärkerer, konformer und betrieblich solider Lizenznehmer zu etablieren“, sagte Dyck.

Über RavenQuest BioMed Inc.

RavenQuest BioMed Inc. ist ein diversifiziertes, börsennotiertes Cannabisunternehmen und betreibt Geschäftsbereiche, die auf die Cannabisproduktion, Management- und Beratungsleistungen sowie spezielle Forschung und Entwicklung spezialisiert sind. RavenQuest ist ein lizenzierter Produzent mit Betriebsanlagen in Markham (Ontario) und Edmonton (Alberta). RavenQuest unterhält eine Forschungspartnerschaft mit der McGill University in Montreal, in deren Mittelpunkt die Identifizierung von Sorten, die Pflanzenstabilisierung sowie die Ertragsmaximierung der Cannabispflanze stehen. Das Unternehmen richtet sein Hauptaugenmerk auf Partnerschaften mit indigenen Gemeinschaften.

Für das Board of Directors von
RAVENQUEST BIOMED INC.

„George Robinson“
Chief Executive Officer

Weitere Informationen erhalten Sie über:
Mathieu McDonald, Corporate Communications – 604-484-1230

In Europa:
Swiss Resource Capital AG
Jochen Staiger

info@resource-capital.ch

https://www.resource-capital.ch/

Die Canadian Securities Exchange und deren Regulierungsorgane (in den Statuten der Canadian Securities Exchange als „Regulation Services Provider“ bezeichnet) übernehmen keinerlei Verantwortung für die Angemessenheit oder Genauigkeit dieser Meldung, die von der Unternehmensführung erstellt wurde.

Hinweise bezüglich zukunftsgerichteter Aussagen

Sämtliche in dieser Pressemeldung enthaltenen Aussagen, mit Ausnahme von Aussagen über historische Fakten, sind im Hinblick auf das Unternehmen als „zukunftsgerichtete Informationen“ im Sinne der geltenden Wertpapiergesetze zu verstehen, einschließlich Aussagen über die zukünftige Entwicklung von Bonify. Mit diesen zukunftsgerichteten Aussagen verfolgt das Unternehmen den Zweck, Informationen über die aktuellen Erwartungen und Pläne im Hinblick auf die Zukunft bereitzustellen. Die Leser werden darauf hingewiesen, dass solche Aussagen für andere Zwecke möglicherweise nicht geeignet sind. Diese Informationen sind naturgemäß mit typischen Risiken und Unsicherheiten behaftet, die allgemeiner oder spezifischer Natur sein können und dazu führen könnten, dass sich Erwartungen, Prognosen, Vorhersagen oder Schlussfolgerungen als unrichtig herausstellen, dass Annahmen nicht der Wahrheit entsprechen und dass Ziele, strategische Vorgaben und Prioritäten nicht erreicht werden. Zu diesen Risiken und Unsicherheiten zählen unter anderem auch jene, die in den öffentlichen Unterlagen des Unternehmens identifiziert und aufgelistet sind und im Firmenprofil auf SEDAR (www.sedar.com) veröffentlicht wurden. Das Unternehmen hat sich bemüht, wichtige Faktoren aufzuzeigen, die dazu führen können, dass die tatsächlichen Ereignisse oder Ergebnisse wesentlich von jenen abweichen, die in den zukunftsgerichteten Informationen beschrieben sind. Es können aber auch andere Faktoren dazu führen, dass die Ereignisse oder Ergebnisse nicht wie erwartet, geschätzt oder beabsichtigt ausfallen. Es kann nicht garantiert werden, dass sich solche Informationen als wahrheitsgemäß herausstellen. Tatsächliche Ergebnisse und zukünftige Ereignisse können unter Umständen erheblich von solchen Aussagen abweichen. Das Unternehmen hat, sofern nicht gesetzlich vorgeschrieben, weder die Absicht noch die Verpflichtung, zukunftsgerichtete Informationen aufgrund neuer Erkenntnisse, zukünftiger Ereignisse bzw. sonstiger Umstände zu aktualisieren oder zu korrigieren.

Die Ausgangssprache (in der Regel Englisch), in der der Originaltext veröffentlicht wird, ist die offizielle, autorisierte und rechtsgültige Version. Diese Übersetzung wird zur besseren Verständigung mitgeliefert. Die deutschsprachige Fassung kann gekürzt oder zusammengefasst sein. Es wird keine Verantwortung oder Haftung für den Inhalt, die Richtigkeit, die Angemessenheit oder die Genauigkeit dieser Übersetzung übernommen. Aus Sicht des Übersetzers stellt die Meldung keine Kauf- oder Verkaufsempfehlung dar! Bitte beachten Sie die englische Originalmeldung auf www.sedar.com,www.sec.gov, www.asx.com.au/ oder auf der Firmenwebsite!

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

11th International Symposium: „Advanced Battery Power – Kraftwerk Batterie“

Modern life thrives on the availability of electrical energy. Countless applications spanning from medical to industrial and consumer products have been made possible only by modern battery technology. Future electric vehicles will have ranges of 450 km and more. Nowadays, batteries are an integral technological component in home solar energy installations and in the electricity grid generally, and their importance is growing dramatically.  

Even both, limited energy density and high costs, sectors such as mobility, communications, renewable energy, count on the development of rising storage performances with regard to price, mass and energy.

Reason enough for researchers, application engineers, developers to join the 11th International meeting,“Advanced Battery Power – Kraftwerk Batterie” held in Aachen, Germany, from April 3rd-4th, 2019, gathering academia, industry and the public sector. Over 600 visitors are expected. The latest version of the program is now on-line (www.battery-power.eu).

With Dr. Matthias Ullrich, Volkswagen Aktiengesellschaft, Prof. Rachid Yazami, Nanyang Technological University, Dr. Hartung Wilstermann, Webasto E-Solutions & Services Boards, Prof. Dr. Petr Novàk, Paul Scherrer Institut, Prof. Dr. Kristina Edström, Uppsala University and Ted Miller (requested), Ford Motor Company

the conference has already attracted international and renowned scientists and practitioners.

The “Battery Day NRW” preceding the main symposium on April 2nd will enable participants to keep abreast with various topics around the basic science and technology by means of a thoroughly adapted series of introductory seminars. The “Battery Day NRW” is supported by the Department of Economy, Innovation, Digitalization and Energy of the State of North Rhine-Westphalia and held under the patronage of Prof. Dr. Andreas Pinkwart.

From April 2rd – 4rd, 2019, Aachen will again be the platform to update on, discuss, and experience hands-on the latest developments in battery technology, research, development and examples of applications.

The conference language will be English and German (Battery Day NRW). Further details can be found under www.battery-power.eu. The exhibition is already fully booked.

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

FOBA showcasing at Intec and MD&M West

FOBA Laser Marking + Engraving is attending two international trade shows in February to present innovative direct part marking solutions: At both the Intec in Leipzig/Germany (Feb. 5 – 8, 2019) and the MD&M West in Anaheim/USA (Feb. 5 – 7, 2019), a FOBA M2000 laser marking system will be presented on-site at the booth.

The trade show presentation also includes the recently introduced technology FOBA Mosaic™ for fixture-less laser marking. FOBA Mosaic™ works with a camera that is integrated directly in the marking head. The vision-system creates a view of the entire marking field without optical distortion and enables an automated laser mark-alignment. Expensive product fixtures therefore become unnecessary, which means essential cost-savings.

The showcased laser marking machine FOBA M2000-P will be equipped with a 20 Watt fiber laser and the integrated software MarkUS 2.12, also including FOBA Mosaic™. At the Intec FOBA will also present the FOBA Y.1000, a powerful 100 Watt laser marker for the integration in high-throughput production lines that specifically complies with high-speed manufacturing requirements.

Apart from the live presentations at the booth, FOBA is also hosting two lectures at the Intec: On February 7th, Dr. Faycal Benayad-Cherif will be speaking about the innovations offered by FOBA Mosaic™ marking solution (2:30 p.m., lecture in English language). On February 8th, medical market expert Christian Söhner will provide information about UDI-compliant laser marking of medical products (11:20 a.m., lecture in German language).

Intec (trade fair for the metal processing industry), February 5-8, 2019, Leipzig fair, Germany
FOBA booth: Hall 2, stand B59

MD&M West (medical industry trade show), February 5-7, 2019, Anaheim Convention Center, Anaheim, CA, USA (#AdvMfgExpo)
FOBA booth: Hall E, stand 360

FOBA Laser Marking + Engraving
www.fobalaser.com

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox

OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe

OncoBeta® GmbH located at the Garching Technology and Start-up Centre, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is proud to announce that it is listed as one of the Top 20 MedTech Solution Providers in Europe in 2018 by MedTech Outlook.

The jury consisting of CEOs, CIOs, VCs, industry analysts and MedTech Outlook´s editorial board members selected OncoBeta GmbH and its Rhenium-SCT® therapy as one of the companies that exhibit innovative technologies and strategies. With this award OncoBeta® GmbH belongs to the forefront of providing innovative solutions to solve the increasing complexities in healthcare environments and improve the quality of care.

„Being one of the first healthcare service providers to have successfully developed and commercialized radioisotope therapy for the treatment of non-melanoma skin cancer, it is our goal to provide patients and healthcare professionals with the most efficient and innovative therapies possible “, states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH.

View the Top 20 MedTech Solution Providers in Europe under the Digital Magazine Link at:
https://www.medicaltechoutlook.com/magazines/December2018/MedTech_Europe/#page=14

Read the Interview with Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH directly at:
https://europe.medicaltechoutlook.com/vendor/oncobeta-commercialized-radioisotope-cancer-therapy-cid-210-mid-27.html

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients’ lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.

Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:
LinkedIn: https://www.linkedin.com/…

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

 

Originalmeldung direkt auf PresseBox lesen
Mehr von Firma PresseBox